CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 98 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2018. The put-call ratio across all filers is 0.96 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $0 | – | 11,200 | +9.8% | 0.00% | – |
| Q2 2018 | $0 | – | 10,200 | -59.5% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 25,200 | -2.7% | 0.00% | – |
| Q3 2017 | $1,000 | -66.7% | 25,900 | +2.4% | 0.00% | – |
| Q2 2017 | $3,000 | -57.1% | 25,300 | 0.0% | 0.00% | – |
| Q1 2017 | $7,000 | -68.2% | 25,300 | -4.9% | 0.00% | -100.0% |
| Q4 2016 | $22,000 | +10.0% | 26,600 | -2.2% | 0.00% | 0.0% |
| Q3 2016 | $20,000 | +53.8% | 27,200 | -72.8% | 0.00% | 0.0% |
| Q2 2016 | $13,000 | -84.1% | 100,000 | -36.0% | 0.00% | -83.3% |
| Q1 2016 | $82,000 | -89.9% | 156,200 | +203.1% | 0.01% | -84.6% |
| Q4 2015 | $808,000 | +5.9% | 51,539 | -28.8% | 0.04% | -2.5% |
| Q3 2015 | $763,000 | -68.5% | 72,365 | -24.8% | 0.04% | -72.6% |
| Q2 2015 | $2,426,000 | -10.4% | 96,196 | -11.3% | 0.15% | -20.2% |
| Q1 2015 | $2,707,000 | +7419.4% | 108,403 | +231.5% | 0.18% | +18200.0% |
| Q4 2014 | $36,000 | +200.0% | 32,700 | +46.6% | 0.00% | – |
| Q3 2014 | $12,000 | – | 22,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |